Objective To study therapeutic effects and underlying mechanisms of diammonium glycyrrhizinate lipid ligand (DGLL) on nonalcoholic fatty liver disease (NAFLD). Methods Sixty SD rats were randomly divided into six groups(10 rats per group): the model group, 3 DGLL-treated (30, 60, 120mg/kg) groups, the positive control ［treated with biphenyldicarboxylate (200mg/kg)］ group and normal control group. The stomach of the rat of the model group was irrigated with high lipid emulsion. The rats of DGLL groups were irrigated with relative dose of DGLL. After nine weeks, the changes of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) in serum and the contents of malondialdehyde (MDA), superoxide dismutase (SOD) in liver homogenate were measured; the NF-κB p65 level in liver tissues was observed by immunohistochemistry, respectively. The expressions of NF-κB p65 and I-κBα in liver were determined by Western blotting. BR>Results Compared with the model group, the levels of TC，TG，LDL，MDA were decreased, meanwhile the activity of HDL and SOD were enhanced, the level of NF-κB in liver tissues was ameliorated remarkably by administration of DGLL. Meanwhile, th